With Kyprolis Advancing, Millennium Stakes Faith In Oral Velcade Successor
Executive Summary
Takeda/Millennium’s oral weekly proteasome inhibitor MLN9708 looked effective with a mild neuropathy profile in a new myeloma study presented at the American Society of Hematology meeting, and Takeda has committed to large Phase III trials. There’s no time to lose – mid-stage studies presented for Onyx’ rival Kyprolis, currently approved for relapsed myeloma, support moving that drug to the frontline.
You may also be interested in...
Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test
Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.
Takeda’s Weekly Oral Proteasome Inhibitor Ixazomib Passes First Pivotal Test
Company plans to submit data from positive TOURMALINE-MM1 study of Velcade follow-on ixazomib in relapsed myeloma to regulators; drug set for 2015 filing.
Onyx Starts Acquisition Process; Price And Competition To Come Into Play
The fast-growing biotech is soliciting bids, after a rejected Amgen offer and additional third party interest. Wall Street is scrambling to determine how to value Onyx and who the bidders could be.